Home > Insider Trading > Filing (0001209191-15-034714)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1337553	Aerie Pharmaceuticals Inc	AERI	Biological Products, (No Disgnostic Substances) (2836)	203109565

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1590102	Anand Mehra	C/O Sofinnova Ventures 3000 Sand Hill Road, 4-250 Menlo Park CA 94025		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-04-14	150,000	$5.00	916,657	No	4	X	Indirect	See footnote
Common Stock	Disposition	2015-04-14	22,066	$5.00	894,591	No	4	J	Indirect	See footnote
Common Stock	Disposition	2015-04-14	130,702	$34.08	763,889	No	4	S	Indirect	See footnote
Common Stock	Disposition	2015-04-15	294,298	$33.45	469,591	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Indirect	See footnote
No	4	J	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock Warrant (right to buy)	Disposition	2015-04-14	150,000	$0.00	150,000	$5.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	X	Indirect

Footnotes

Sofinnova Venture Partners VII, L.P. ("SV VII") net exercised the warrant by its terms, which allowed SV VII to pay the exercise price of the warrant by forfeiting a portion of the exercised warrant shares with a value equal to the aggregate exercise price.
The securities are owned directly by SV VII. Sofinnova Management VII, L.L.C. ("SV VII LLC"), the general partner of SV VII, James Healy, Michael Powell and Eric Buatois, the managing members of SV VII LLC, and Anand Mehra, a director of the issuer, may be deemed to have shared voting power and dispositive power over the shares owned by SV VII. Such persons and entities disclaim beneficial ownership over the shares held by SV II except to the extent of any pecuniary interest therein.
Represents shares withheld by the Issuer in connection with the net exercise of the common stock warrant pursuant to its terms.
Prior to the Issuer's initial public offering, SV VII held Series A-4 warrants to purchase shares of the Issuer's Series A-4 convertible preferred stock. Such warrants were exercisable at a price of $1.00 per share at any time during their ten year term (expiration is August 2020), subject to adjustment. Upon completion of the Issuer's initial public offering, the Series A-4 warrants automatically became exercisable for 150,000 shares of the Issuer's common stock at an exercise price of $5.00 per share.